Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
OssDsign AB (publ) (OSSD.ST)
Uppsala, SE
OssDsign AB (publ) specializes in the innovation, manufacturing, and distribution of advanced implant and material technologies crucial for bone regeneration. The company operates across a broad international market, including Sweden, Germany, the United States, the United Kingdom, the wider European region, and other global territories. Its product line features OSSDSIGN cranial, a comprehensive implant and accessory system engineered for the reconstruction of skull defects in cranioplasty procedures. Another key offering, OSSDSIGN facial, is designed to correct skeletal deformities, whether they arise from trauma or are congenital. Additionally, OssDsign provides the OSSDSIGN Cranioplug, which serves to secure bone flaps and cover burr holes, and OssDsign Catalyst, a cutting-edge nanosynthetic bone graft substitute specifically formulated to stimulate healthy bone tissue formation. Established in 2011, the company maintains its primary operational base in Uppsala, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.74% | +6.06% | +20.00% | -31.60% | -63.35% | -62.83% | -70.51% | -38.42% | -53.59% | -81.74% | -81.74% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+34.5% ★ Q1'26: -17.1% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+8.0% Q1'26: +33.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-34.8% Q1'26: -40.3% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-26.0% Q1'26: -35.9% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-38.9% Q1'26: -40.6% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+11.2% Q1'26: +13.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.03× Q1'26: -0.02× (vs Q1'25)
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
24.87M
est: 26.77M (-7.1%)
|
31.73M
est: 31.45M (+0.9%)
|
56.99M
est: 54.45M (+4.7%)
|
112.16M
est: 123.46M (-9.2%)
|
133.94M
est: 129.52M (+3.4%)
|
180.16M
est: 181.46M (-0.7%)
|
167.80M
162.80M – 175.55M
-7.5% YoY
|
238.20M
235.35M – 242.02M
+42.0% YoY
|
308.95M
308.79M – 309.11M
+29.7% YoY
|
| EBITDA |
-80.64M
est: -23.22M (-247.2%)
|
-79.97M
est: -27.29M (-193.0%)
|
-89.41M
est: -47.24M (-89.3%)
|
-122.02M
est: -88.84M (-37.4%)
|
-45.31M
est: -93.20M (+51.4%)
|
-46.76M
est: -130.57M (+64.2%)
|
-120.75M
-126.32M – -117.15M
+7.5% YoY
|
-171.40M
-174.15M – -169.35M
-42.0% YoY
|
-222.31M
-222.42M – -222.20M
-29.7% YoY
|
| EBIT |
-83.93M
est: -23.37M (-259.1%)
|
-89.70M
est: -27.46M (-226.6%)
|
-90.23M
est: -47.54M (-89.8%)
|
-130.22M
est: -89.51M (-45.5%)
|
-48.06M
est: -93.91M (+48.8%)
|
-46.76M
est: -131.57M (+64.5%)
|
-121.66M
-127.28M – -118.04M
+7.5% YoY
|
-172.71M
-175.48M – -170.64M
-42.0% YoY
|
-224.00M
-224.12M – -223.89M
-29.7% YoY
|
| Net Income |
-84.59M
est: -268.38M (+68.5%)
|
-93.92M
est: -154.36M (+39.2%)
|
-99.39M
est: -158.90M (+37.5%)
|
-130.49M
est: -139.48M (+6.4%)
|
-49.66M
est: -56.11M (+11.5%)
|
-50.99M
est: -40.74M (-25.1%)
|
-46.10M
-61.89M – -44.70M
-13.2% YoY
|
-31.70M
-41.55M – -30.01M
+31.2% YoY
|
-10.49M
-10.88M – -10.10M
+66.9% YoY
|
| SGA |
38.47M
est: 35.01M (+9.9%)
|
46.03M
est: 41.14M (+11.9%)
|
64.36M
est: 71.22M (-9.6%)
|
143.44M
est: 150.95M (-5.0%)
|
151.96M
est: 158.35M (-4.0%)
|
201.71M
est: 221.86M (-9.1%)
|
205.16M
199.05M – 214.63M
-7.5% YoY
|
291.24M
287.74M – 295.91M
+42.0% YoY
|
377.73M
377.54M – 377.93M
+29.7% YoY
|
| EPS |
-3.36
est: -2.70 (-24.3%)
|
-1.94
est: -1.55 (-24.8%)
|
-1.70
est: -1.60 (-6.2%)
|
-1.59
est: -1.26 (-26.7%)
|
-0.50
est: -0.51 (+1.0%)
|
-0.46
est: -0.37 (-25.5%)
|
-0.46
-0.56 – -0.40
-25.5% YoY
|
-0.31
-0.38 – -0.27
+32.6% YoY
|
-0.10
-0.10 – -0.09
+69.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mark Waugh | Chief Executive Officer | 8M | male |
| Anders Svensson | Chief Financial Officer | — | male |
| Eric Patermo | Vice President of Sales US | — | male |
| Melanie Marshall | Vice President of Clinical & Medical Affairs | — | female |
| Stephen Anderson | Vice President of Marketing | — | male |
| Tom Buckland | Chief Technical Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OSSD.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
